The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Targeting immunosuppressive adenosine in cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
The 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,781
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Cited by
Single-cell reconstruction of the early maternal–fetal interface in humans
Vento-Tormo, R., Efremova, M., Botting, R. A., Turco, M. Y., Vento-Tormo, M., Meyer, K. B., Park, J.-E., Stephenson, E., Polański, K., Goncalves, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0698-6 · Cited by 2,358
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Self-citationCD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
Farhood, B., Najafi, M., & Mortezaee, K. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27782 · Cited by 1,658
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
Self-citationMyeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 723
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
Yeast surface display platform for rapid discovery of conformationally selective nanobodies
McMahon, C., Baier, A. S., Pascolutti, R., Wegrecki, M., Zheng, S., Ong, J. X., Erlandson, S. C., Hilger, D., Rasmussen, S. G. F., Ring, A. M., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0028-6 · Cited by 546
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Self-citationEmerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 510
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
From purines to purinergic signalling: molecular functions and human diseases
Huang, Z., Xie, N., Illes, P., Di Virgilio, F., Ulrich, H., Semyanov, A., Verkhratsky, A., Sperlagh, B., Yu, S.-G., Huang, C., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00553-z · Cited by 489
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
Vesely, M. D., Zhang, T., & Chen, L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-070621-030155 · Cited by 468
Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance
Sherman, M. H., & Beatty, G. L. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031621-024600 · Cited by 467
Nucleotide metabolism: a pan-cancer metabolic dependency
Mullen, N. J., & Singh, P. K. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00557-7 · Cited by 466
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 421
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
Chen, D., Zhang, X., Li, Z., & Zhu, B. (2021) · Theranostics · doi:10.7150/thno.51777 · Cited by 390
CD39/CD73/A2AR pathway and cancer immunotherapy
Xia, C., Yin, S., To, K. K. W., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01733-x · Cited by 399
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 354
Adenosine Metabolism: Emerging Concepts for Cancer Therapy
Boison, D., & Yegutkin, G. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.007 · Cited by 336
Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth
Davidson, S., Efremova, M., Riedel, A., Mahata, B., Pramanik, J., Huuhtanen, J., Kar, G., Vento-Tormo, R., Hagai, T., Chen, X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107628 · Cited by 323
Moesta, A. K., Li, X.-Y., & Smyth, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0376-4 · Cited by 322
Self-citationMetastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Li, J., Duran, M. A., Dhanota, N., Chatila, W. K., Bettigole, S. E., Kwon, J., Sriram, R. K., Humphries, M. P., Salto-Tellez, M., James, J. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0387 · Cited by 312
Sacdalan, D. B., Lucero, J. A., & Sacdalan, D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153290 · Cited by 306
Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., & Ciardiello, F. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.003 · Cited by 304
Cords, L., Engler, S., Haberecker, M., Rüschoff, J. H., Moch, H., de Souza, N., & Bodenmiller, B. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.021 · Cited by 304
Monalizumab: inhibiting the novel immune checkpoint NKG2A
van Hall, T., André, P., Horowitz, A., Ruan, D. F., Borst, L., Zerbib, R., Narni-Mancinelli, E., van der Burg, S. H., & Vivier, E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0761-3 · Cited by 292
Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses
Chen, Q., Chen, M., & Liu, Z. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00271e · Cited by 288
Manganese‐Based Tumor Immunotherapy
Zhang, K., Qi, C., & Cai, K. (2023) · Advanced Materials · doi:10.1002/adma.202205409 · Cited by 288
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Li, X.-Y., Moesta, A. K., Xiao, C., Nakamura, K., Casey, M., Zhang, H., Madore, J., Lepletier, A., Aguilera, A. R., Sundarrajan, A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0541 · Cited by 264
Self-citationTurning up the heat on non-immunoreactive tumours: opportunities for clinical development
Ochoa de Olza, M., Navarro Rodrigo, B., Zimmermann, S., & Coukos, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30234-5 · Cited by 256
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
Samanta, D., & Semenza, G. L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.002 · Cited by 190
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
Tumor-Derived Adenosine Promotes Macrophage Proliferation in Human Hepatocellular Carcinoma
Wang, J., Wang, Y., Chu, Y., Li, Z., Yu, X., Huang, Z., Xu, J., & Zheng, L. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.021 · Cited by 133
Vaupel, P., & Multhoff, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01887 · Cited by 81
“have extensively reviewed the current approaches (35).”
Xie, Y., Wang, X., Wang, W., Pu, N., & Liu, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06422-5 · Cited by 80
“Adenosine receptors are widely expressed across immune cells (CTLs, Mφ, DCs), thereby exerting a broader immunosuppressive effect [115, 116].”
Dysregulation of ectonucleotidase-mediated extracellular adenosine during postmenopausal bone loss
Shih, Y.-R. V., Liu, M., Kwon, S. K., Iida, M., Gong, Y., Sangaj, N., & Varghese, S. (2019) · Science Advances · doi:10.1126/sciadv.aax1387 · Cited by 77
Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade5111 · Cited by 65
Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
Pasquini, S., Contri, C., Cappello, M., Borea, P. A., Varani, K., & Vincenzi, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1030895 · Cited by 29
Metadata
- Authors
- Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J.
- Venue
- Nature Reviews Cancer
- Published
- 2017-12
- Volume
- 17
- Issue
- 12
- Pages
- 709-724
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2765132620
- Cited by
- 840
- References
- 133
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.